<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>337</serviceExecutionTime><Drug id="12329"><DrugName>INS-1</DrugName><DrugSynonyms><Name><Value>INS-1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>D-chiro-inositol, Insmed</Value></Name><Name><Value>diabetes therapeutics, Insmed</Value></Name><Name><Value>inositol phosphoglycans, Insmed</Value></Name></DrugSynonyms><CompanyOriginator id="23330">Insmed Inc</CompanyOriginator><CompaniesSecondary><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Company id="23330">Insmed Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="12329" type="Drug"><TargetEntity id="222448" type="siDrug">D-Chiroinositol</TargetEntity></SourceEntity><SourceEntity id="20289" type="Company"><TargetEntity id="4295876967" type="organizationId">Taisho Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="23330" type="Company"><TargetEntity id="4295915885" type="organizationId">Insmed Inc</TargetEntity></SourceEntity><SourceEntity id="1699" type="ciIndication"><TargetEntity id="E28.2" type="ICD10"></TargetEntity><TargetEntity id="10036049" type="MEDDRA"></TargetEntity><TargetEntity id="D011085" type="MeSH"></TargetEntity><TargetEntity id="-1653169239" type="omicsDisease"></TargetEntity><TargetEntity id="1175" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="655" type="ciIndication"><TargetEntity id="10058097" type="MEDDRA"></TargetEntity><TargetEntity id="D008659" type="MeSH"></TargetEntity><TargetEntity id="-652126003" type="omicsDisease"></TargetEntity><TargetEntity id="961" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="60" type="Action"><TargetEntity id="1746" type="Mechanism">Androgen Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1919" type="Action"><TargetEntity id="605" type="Mechanism">Insulin Sensitizers</TargetEntity></SourceEntity><SourceEntity id="PTGT-00135" type="ciTarget"><TargetEntity id="9904399853673" type="siTarget">Androgen receptor</TargetEntity><TargetEntity id="4423" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1699">Polycystic ovary syndrome</Indication><Indication id="655">Metabolic disorder</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="1052">Unspecified enzyme stimulator</Action><Action id="60">Androgen receptor antagonist</Action><Action id="1919">Insulin sensitizer</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-12-04T11:38:42.000Z</LastModificationDate><ChangeDateLast>2017-04-06T00:00:00.000Z</ChangeDateLast><AddedDate>1996-05-16T10:27:55.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="20289" linkType="Company"&gt;Taisho&lt;/ulink&gt; and &lt;ulink linkID="23330" linkType="Company"&gt;Insmed&lt;/ulink&gt; were developing INS-1, a novel inositol phosphoglycan mediator of the insulin signal transduction pathway, for the potential treatment of diabetes and polycystic ovarian syndrome (PCOS). By July 2000, INS-1 was undergoing phase II trials for PCOS and type 2  diabetes [&lt;ulink linkID="376544" linkType="reference"&gt;376544&lt;/ulink&gt;] [&lt;ulink linkID="451687" linkType="reference"&gt;451687&lt;/ulink&gt;], and by May 2002, phase IIb trials in the US for both indications were ongoing [&lt;ulink linkID="453816" linkType="reference"&gt;453816&lt;/ulink&gt;], [&lt;ulink linkID="460177" linkType="reference"&gt;460177&lt;/ulink&gt;]. However, in September 2002, based on phase II trial results, Insmed and Taisho opted to discontinue development of INS-1 [&lt;ulink linkID="463475" linkType="reference"&gt;463475&lt;/ulink&gt;], [&lt;ulink linkID="463773" linkType="reference"&gt;463773&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;POLYCYSTIC OVARIAN SYNDROME&lt;/subtitle&gt;In September 2002, Insmed reported phase II data from patients with PCOS, showing that INS-1 was safe and well tolerated but did not achieve significance on its primary efficacy measures. Although an overall increase in ovulation rates was not achieved, an increased number of pregnancies occurred in the INS-1 treated patients. At this time, the company was evaluating the clinical relevance of this observation and whether it warranted further investigation, but had decided to discontinue development of INS-1 for diabetes and PCOS based on these, and other clinical results [&lt;ulink linkID="463475" linkType="reference"&gt;463475&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Insmed reported positive results in two phase II trials, one in obese women with polycystic ovarian syndrome (PCOS) and one in dyslipidemia in non-diabetic subjects in late February 2001 [&lt;ulink linkID="400303" linkType="reference"&gt;400303&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The PCOS trial in obese women was a double-blind, placebo-controlled, dose range-finding study designed to evaluate the incidence of hyperandrogenic anovulation in women diagnosed with PCOS and the effects of INS-1 in this population. Subjects (223) received a single, daily oral dose of INS-1 (300, 600 or 1200 mg) or placebo for 2 months. The key findings from this trial were that 71 obese anovulatory women were found to be hyperandrogenic, based on serum testosterone measurements. Of these women, 67 completed at least 1 month of INS-1 administration; in this population, a significant difference in ovulation rates between the treatment groups was observed (placebo 18%, 300 mg 6%, 600 mg 32%, and 1200 mg 44%; p &amp;lt; 0.05). In those women who received INS-1 and ovulated, a corresponding significant reduction in both free and total serum testosterone concentrations was observed (1200 mg/day: 22% reduction in free testosterone and 20% reduction in total testosterone, p &amp;lt; 0.05). INS-1 was well tolerated in all subjects [&lt;ulink linkID="400303" linkType="reference"&gt;400303&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The phase II dyslipidemia trial was an exploratory, double-blind, placebo-controlled study designed to evaluate the effects of INS-1 on lipid profiles in non-diabetic dyslipidemic subjects. A total of 61 subjects received a single, oral daily dose of 1200 mg of INS-1 for 3 months. The key findings from this trial were that in placebo-treated subjects, LDL cholesterol levels significantly worsened over the course of the study (an increase of 14 mg/dl, p &amp;lt; 0.05), whereas in subjects receiving INS-1, there was no significant change. In those subjects with elevated LDL cholesterol (&amp;gt; 130 mg/dl) at the beginning of the study, treatment with INS-1 caused a significant improvement when compared to placebo (a decrease of 21 mg/dl compared to an increase of 30 mg/dl, p &amp;lt; 0.05); in placebo-treated subjects, a trend toward a modest elevation of total cholesterol levels over the course of the study was observed, whereas triglyceride levels did not change. In subjects treated with INS-1, there was no change in total cholesterol. However, a significant reduction from baseline triglyceride levels was observed; apolipoprotein B levels decreased by 9 mg/dl (p &amp;lt; 0.05) in the INS-1 treated group compared to no significant reduction in the placebo group. The drug was well tolerated in all subjects [&lt;ulink linkID="400303" linkType="reference"&gt;400303&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a randomized, double-blind, phase II trial presented at the annual meeting of the Endocrine Society in June 2000, INS-1 was found to enhance ovulation rates, lower diastolic and systolic blood pressure and improve lipid profiles in lean women with PCOS [&lt;ulink linkID="372168" linkType="reference"&gt;372168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; INS-1 was under investigation for the treatment of PCOS in a multi-site trial. Preliminary data from the trial, announced in January 1998, show that INS-1 has potential in the treatment of PCOS. The 30 women were administered a single dose of INS-1 for up to 6 weeks. At the end of the study period, 93% of the treated women had ovulated, as compared to 27% of the placebo group [&lt;ulink linkID="276340" linkType="reference"&gt;276340&lt;/ulink&gt;]. At the end of the study, involving a total of 44 obese women, 86% (19 of 22) of treated women had ovulated, compared to only 27% (6 of 22) women in the placebo group. Drug treated women also experienced significant decreases in serum insulin and testosterone levels. Treatment with INS-1 also resulted in an improvement in risk factors of coronary artery disease by reducing triglycerides and blood pressure [&lt;ulink linkID="289543" linkType="reference"&gt;289543&lt;/ulink&gt;], [&lt;ulink linkID="303921" linkType="reference"&gt;303921&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;DIABETES&lt;/subtitle&gt;In September 2002, Insmed reported that in a trial in patients with type  2 diabetes, INS-1 was safe and well tolerated but did not achieve significance on its primary efficacy measures. These efficacy results failed to corroborate those reported in several previous studies, and on the strength of these, and other data, the company decided to discontinue development of INS-1 [&lt;ulink linkID="463475" linkType="reference"&gt;463475&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2002, Insmed presented INS-1 data from a phase II trial, involving patients with type  2 diabetes receiving sulfonylurea therapy, at the 62nd ADA Scientific Sessions in San Francisco, CA. An analysis of lipid profiles revealed patients receiving INS-1 treatment but no statin therapy experienced a modest improvement in total cholesterol and LDL cholesterol, compared to patients receiving placebo. Those receiving INS-1 concurrently with statin therapy experienced even greater improvements in total cholesterol, LDL cholesterol and apolipoprotein-B. In a second presentation, data from the same study demonstrated that INS-1 improved pancreatic beta cell function and glycemic control. Subjects receiving INS-1 concurrently with a sulfonylurea did not demonstrate the expected insulin secretion decay associated with chronic sulfonylurea use. Instead, these patients experienced a significant improvement in pancreatic insulin production in response to a meal challenge, compared to patients receiving a placebo. Patients receiving INS-1 also experienced a significant improvement in several measures of glycemic control including HbA1c, glucose and fructosamine [&lt;ulink linkID="454248" linkType="reference"&gt;454248&lt;/ulink&gt;], [&lt;ulink linkID="456641" linkType="reference"&gt;456641&lt;/ulink&gt;], [&lt;ulink linkID="454975" linkType="reference"&gt;454975&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2001, Insmed announced positive results following full analysis of it completed phase II trial of type  2 diabetes patients, treated with INS-1 in combination with sulfonylureas. Those patients who received both INS-1 and a sulfonylurea showed a significant improvement in glycohemoglobin (HbA1c) of 0.36% compared to patients receiving a sulfonylurea alone. In addition, the improvement in HbA1c was more pronounced in those patients who were either better controlled by the sulfonylurea therapy of had a less severe for of their disease as judged by the baseline fasting plasma glucose [&lt;ulink linkID="395112" linkType="reference"&gt;395112&lt;/ulink&gt;], [&lt;ulink linkID="412612" linkType="reference"&gt;412612&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company completed a phase II study of INS-1 against type  2 diabetes in March 1999. This was a 1-month, double-blind, placebo-controlled, multicenter study in which 110 subjects were enrolled. Drug treatment resulted in statistically significant improvements in glycemic control parameters and lipid profiles [&lt;ulink linkID="383571" linkType="reference"&gt;383571&lt;/ulink&gt;]. The drug was well tolerated [&lt;ulink linkID="318319" linkType="reference"&gt;318319&lt;/ulink&gt;], [&lt;ulink linkID="331741" linkType="reference"&gt;331741&lt;/ulink&gt;]. However, data from a preliminary intent-to-treat analysis showed that type  2 diabetics treated with INS-1 in combination with sulfonylureas showed no statistical significance from placebo [&lt;ulink linkID="391271" linkType="reference"&gt;391271&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Insmed has completed a phase I study of INS-1 in the UK, for the potential treatment of type  2 diabetes. The single dose, three phase, controlled, crossover study randomized subjects to INS-1 (300 mg, 600 mg, 1200 mg) or placebo. The study was designed to evaluate the safety and tolerability of INS-1, examine the effect of INS-1 on insulin sensitivity, and provide preliminary absorption and dose response information. INS-1 was well tolerated with no safety concerns and indicated promising preliminary efficacy. Insmed has also initiated phase I studies for diabetes in the US. These studies were to expand the available safety, pharmacokinetic and preliminary efficacy data, including those from the UK phase I trials, and were designed to form a solid foundation on which to base a phase II program to investigate INS-1 in an insulin resistant population [&lt;ulink linkID="253735" linkType="reference"&gt;253735&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;INS-1 has also been stated to have therapeutic potential for the treatment of metabolic disorders and infectious diseases due to insulin-resistance, such as hypertension, obesity, coronary artery disease and syndrome X [&lt;ulink linkID="239789" linkType="reference"&gt;239789&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company received a $0.1 million SBIR grant to evaluate applications of this technology in PCOS in 1997 [&lt;ulink linkID="253735" linkType="reference"&gt;253735&lt;/ulink&gt;]. In 1999 the company received a Phase II SBIR grant for the same indication [&lt;ulink linkID="318319" linkType="reference"&gt;318319&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2000, the company signed a letter of intent with Taisho Pharmaceutical regarding development and commercialization rights to the compound in Japan and other Asian countries. Insmed was to retain the rights to the compound in the rest of the world [&lt;ulink linkID="359645" linkType="reference"&gt;359645&lt;/ulink&gt;], [&lt;ulink linkID="453816" linkType="reference"&gt;453816&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; INS-1 was the first in a series of patented compounds for the treatment of insulin resistance and related metabolic disorders. Insmed was also developing a novel diagnostic product using simple urine and blood tests for detection of insulin resistance and impaired glucose tolerance. &lt;/para&gt;&lt;para&gt;As well as the insulin signal transduction pathway, the inositol phosphoglycans have been implicated in other signal pathways, with both paracrine and autocrine effects. They are released from insulin-sensitive tissues in response to insulin, and affect the activity of key glucose utilization enzymes such as PDH. A deficit of these mediators is apparent in insulin-resistant cell lines and in resistant humans. Injection of compounds improves glycemic control in animal models [&lt;ulink linkID="207445" linkType="reference"&gt;207445&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23330">Insmed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1699">Polycystic ovary syndrome</Indication><StatusDate>2002-09-11T00:00:00.000Z</StatusDate><Source id="463475" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23330">Insmed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2002-09-11T00:00:00.000Z</StatusDate><Source id="463475" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1699">Polycystic ovary syndrome</Indication><StatusDate>2002-09-13T00:00:00.000Z</StatusDate><Source id="463773" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23330">Insmed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="655">Metabolic disorder</Indication><StatusDate>2002-09-11T00:00:00.000Z</StatusDate><Source id="463475" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23330">Insmed Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2002-09-11T00:00:00.000Z</StatusDate><Source id="463475" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2002-09-13T00:00:00.000Z</StatusDate><Source id="463773" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23330">Insmed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2001-03-01T00:00:00.000Z</StatusDate><Source id="395112" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23330">Insmed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="655">Metabolic disorder</Indication><StatusDate>1998-11-06T00:00:00.000Z</StatusDate><Source id="303921" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23330">Insmed Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>1998-11-06T00:00:00.000Z</StatusDate><Source id="303921" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23330">Insmed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1699">Polycystic ovary syndrome</Indication><StatusDate>1998-11-06T00:00:00.000Z</StatusDate><Source id="303921" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23330">Insmed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1699">Polycystic ovary syndrome</Indication><StatusDate>1998-02-02T00:00:00.000Z</StatusDate><Source id="276340" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23330">Insmed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>1997-07-09T00:00:00.000Z</StatusDate><Source id="253735" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23330">Insmed Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>1997-03-24T00:00:00.000Z</StatusDate><Source id="239789" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2000-03-17T00:00:00.000Z</StatusDate><Source id="359645" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1699">Polycystic ovary syndrome</Indication><StatusDate>2000-03-17T00:00:00.000Z</StatusDate><Source id="359645" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00135"><Name>Androgen receptor</Name><SwissprotNumbers><Swissprot>O97775</Swissprot><Swissprot>O97776</Swissprot><Swissprot>O97952</Swissprot><Swissprot>O97960</Swissprot><Swissprot>P10275</Swissprot><Swissprot>P15207</Swissprot><Swissprot>P19091</Swissprot><Swissprot>P49699</Swissprot><Swissprot>Q6QT55</Swissprot><Swissprot>Q7T1K4</Swissprot><Swissprot>Q8MIK0</Swissprot><Swissprot>Q9GKL7</Swissprot><Swissprot>Q9TT90</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01028"><Name>Insulin receptor</Name><SwissprotNumbers><Swissprot>P06213</Swissprot><Swissprot>P09208</Swissprot><Swissprot>P15127</Swissprot><Swissprot>P15208</Swissprot><Swissprot>Q28516</Swissprot><Swissprot>Q93105</Swissprot></SwissprotNumbers></Target><Target id="PTGT-02034"><Name>Unspecified enzyme</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1060040">Hospital Clinicas de Caracas</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20289">Taisho Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23330">Insmed Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="124823" title="Insmed and the Medical College of Virginia to collaborate on the development of INS-1"/><Deal id="124833" title="Taisho to develop Insmed's INS-1 in Japan and other Asian countries or polycystic ovary syndrome and type II diabetes"/><Deal id="124835" title="National Institutes of Healt to award Insmed a grant to develop "/></Deals><PatentFamilies><PatentFamily id="1016788" number="WO-09960406" title="Myo-Inositol As A Predictor Of Glycemic Control In Mammals"/><PatentFamily id="1065429" number="WO-00187810" title="Methods for the production of D-chiro-inositol and the use of D-chiro-inositol obtained therefrom"/><PatentFamily id="1356295" number="WO-09959564" title="Pharmaceutical composition comprising D-chiro-inositol for improving insulin sensitivity and glucose metabolism."/><PatentFamily id="1800654" number="WO-09112335" title="Quantitative Analysis Of Chiroinositol As A Diabetic Condition Predictor"/><PatentFamily id="1948539" number="WO-09601996" title="Method Of Detecting Insulin Resistance"/><PatentFamily id="2310019" number="WO-09010439" title="Dietary Supplement For Insulin-Resistant Diabetics"/><PatentFamily id="238160" number="WO-09212706" title="Method of reducing elevated blood sugar levels in humans."/><PatentFamily id="245048" number="WO-09937309" title="Compositions comprising D-chiro-inositol for treating metabolic diseases characterized by hyperinsulinemia, hyperandrogenism, hyperlipidemia and/or anovulation."/><PatentFamily id="246411" number="WO-09959569" title="Benzamide therapeutics for the treatment of inflammatory bowel disease."/><PatentFamily id="394374" number="WO-00064454" title="Compositions and methods for improving insulin sensitivity and glucose metabolism in mammals"/><PatentFamily id="419937" number="WO-00182921" title="Use of D-chiro-inositol in the treatment of conditions associated with hypothalamic gene expression"/><PatentFamily id="464583" number="WO-09625381" title="Method for the production of D-chiroinositol."/><PatentFamily id="616553" number="WO-09408044" title="Screening Method For Diabetic Condition"/><PatentFamily id="793045" number="WO-09010641" title="Purified Insulin Mediators And Purification Process For Same"/><PatentFamily id="816838" number="WO-09010711" title="Screening Method For Diabetic Condition"/><PatentFamily id="917344" number="WO-02099065" title="Compositions and methods for decreasing the risk of or preventing neural tube disorders in mammals"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>7</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ishihara Sangyo Kaisha Ltd" id="17265"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taisho Pharmaceutical Co Ltd" id="20289"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Virginia" id="20695"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centaur Pharmaceuticals Inc" id="21959"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Insmed Inc" id="23330"/><CountAsOwner>7</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>